15 results on '"Kitahara, D."'
Search Results
2. A study of design method of circular patch array absorber for oblique incidence
- Author
-
Kitahara, D., primary, Yoshiizumi, H., additional, Suga, R., additional, Hashimoto, O., additional, and Araki, K., additional
- Published
- 2016
- Full Text
- View/download PDF
3. Harmonic Signal Analysis for Magnetic Nanoparticle Imaging
- Author
-
Othman, N. B., primary, Tsubaki, T., additional, Kitahara, D., additional, Yoshida, T., additional, and Enpuku, K., additional
- Published
- 2014
- Full Text
- View/download PDF
4. Magnetic Nanoparticle Imaging Using Second Harmonic Signals for Sentinel Lymph Node Detection
- Author
-
Othman, N. B., primary, Tsubaki, T., additional, Kitahara, D., additional, Yoshida, T., additional, Enpuku, K., additional, and Kandori, A., additional
- Published
- 2013
- Full Text
- View/download PDF
5. Increased Proportion of the Squamous Cell Carcinoma Components Is Associated with Aggressive Behavior and a Worse Prognosis in Resected Pancreatic Adenosquamous Carcinoma.
- Author
-
Tatsuguchi T, Kitahara D, Kozono S, Date K, Shinkawa T, Kuga H, Tamiya S, Nishihara K, and Nakano T
- Subjects
- Humans, Male, Middle Aged, Aged, Prognosis, Retrospective Studies, Pancreatectomy, Female, Carcinoma, Adenosquamous pathology, Carcinoma, Adenosquamous surgery, Carcinoma, Adenosquamous mortality, Pancreatic Neoplasms pathology, Pancreatic Neoplasms surgery, Pancreatic Neoplasms mortality, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell surgery, Carcinoma, Squamous Cell mortality
- Abstract
Purpose: Pancreatic adenosquamous carcinoma (PASC) is a subtype of pancreatic cancer with a poorer prognosis than pancreatic ductal carcinoma (PDAC). The pathogenesis of this histological subtype has not been fully explained due to its rarity., Methods: Of the 245 patients who underwent pancreatic resection for pancreatic cancer, six (2.3%) were diagnosed with PASC. They were retrospectively allocated to Group A (≥ 50% adenocarcinoma components) or Group S (≥ 50% squamous cell carcinoma components)., Results: The six patients with PASC were all males between the ages of 63 and 77 years, with tumors of 12 to 52 mm in diameter. Tumors were located in the pancreatic head (n = 2) and the pancreatic tail (n = 4). Relative to Group A, all three patients in Group S had larger tumors diameters, ≥ 40 mm with invasion to other organs. Cancer-specific survival of Group S was worse than that of the PDAC group (median survival, 1.5 years vs. 4.1 years). All patients in Group A were alive at the end of follow-up. Recurrence-free survival of Group S was inferior to that of the PDAC group (median survival, 0.2 years vs. 1.8 years; Group A, not defined). Immunohistochemistry revealed the MIB-1 positivity rate in squamous cell carcinoma regions was 1.8 times higher than that in adenocarcinoma regions in the same specimens., Conclusion: In PASC patients, an increased proportion of squamous cell carcinoma components was associated with aggressive behavior and a worse prognosis. This was due to the high MIB-1 positivity rate of squamous cell carcinoma components., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
6. Can FDG-PET after neoadjuvant chemotherapy plus nivolumab predict residual disease in non-small cell lung cancer?
- Author
-
Iguchi H, Akamatsu H, Hirai Y, Nakaya T, Fusamoto A, Yata Y, Nagai T, Kitahara D, Takakura T, Nishimura Y, and Yamamoto N
- Abstract
Neoadjuvant therapy with nivolumab improves event-free survival (EFS) in patients with resectable non-small cell lung cancer, and a pathological complete response is a predictor of longer EFS. We assessed metabolic responses using 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) before and after neoadjuvant treatment to explore its surrogacy for pathological complete response (pCR). We describe three patients with squamous cell lung carcinoma who underwent neoadjuvant therapy with nivolumab plus chemotherapy, followed by surgery. In Cases 1 and 2, preoperative tumour response were PR per RECIST and demonstrated marked metabolic response on FDG-PET after neoadjuvant therapy, with both resected tumours showing a pCR. On the other hand, Case 3 showed a tumour response before surgery (PR per RECIST), however, the tumour, maintained FDG uptake (19.5 → 15.1), and the resected tumour remained residual cells (RVT, 15%). Thus, reduction of FDG uptake on FDG-PET can predict the pathological response to neoadjuvant therapy with nivolumab., Competing Interests: Hiroaki Akamatsu, Honoraria; Amgen Inc, AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol‐Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Nippon Kayaku. Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Pfizer Inc, Takeda Pharmaceutical Co. Ltd. and Taiho Pharmaceutical Co. Ltd. Advisory role; Amgen Inc, and Janssen Pharmaceutical K.K., Sandoz. Research funding; Amgen Inc, Chugai Pharmaceutical Co. Ltd. and MSD K.K. Nobuyuki Yamamoto, Honoraria; AbbVie Inc., Accuray Japan K.K., Amgen K.K., AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Guardant Health Japan Corp., Janssen Pharmaceutical K.K., Merck Biopharma Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., MSD K.K., Kyorin Pharmaceutical Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Pfizer Inc, Takeda Pharmaceutical Co. Ltd. and Taiho Pharmaceutical Co. Ltd., Terumo Corp., Tsumura & Co.. Advisory role; Amgen K.K., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd. Research funding; AbbVie Inc., Amgen K.K., Asahi Kasei Corporation, AstraZeneca K.K., A2 Healthcare Corporation, Boehringer Ingelheim Japan Inc., Bristol‐Myers Squibb K.K., Chugai Pharmaceutical Co. Ltd., EPS Holdings, Inc., IQVIA Services Japan K.K., Janssen Pharmaceutical K.K., Mebix, Inc., MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd.. Data safety Monitoring Board: AstraZeneca K.K. All other authors declare no conflict of interest., (© 2024 The Author(s). Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.)
- Published
- 2024
- Full Text
- View/download PDF
7. Transvaginal resection of a gastrointestinal stromal tumor of the rectum: a case report.
- Author
-
Hatai S, Nagai S, Yoshida T, Matsuoka M, Shinkawa T, Oyama Y, Tanabe Y, Kitahara D, Tamiya S, Amada S, Nishihara K, and Nakano T
- Abstract
Background: The most common curative treatment for gastrointestinal stromal tumors (GISTs) is local excision. For rectal GISTs, however, local excision is difficult because of the anatomical features of the rectum. The optimal surgical approach is still under debate, and less invasive methods are desired. We herein report a case of transvaginal resection of a rectal GIST in a young woman., Case Presentation: A 21-year-old woman was diagnosed with a resectable GIST in the anterior rectal wall and underwent transvaginal tumor resection. The posterior vaginal wall was incised, revealing the tumor fully covered by the rectal mucosa. The rectal adventitia and muscular layer were incised, and the tumor was resected en bloc without rupture. The postoperative course was favorable, and the patient was discharged on postoperative day 12. No findings consistent with recurrence were present 6 months postoperatively., Conclusion: Transvaginal tumor resection is a treatment option as a minimally invasive procedure for GISTs in the anterior rectal wall in female patients., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
8. Neoadjuvant nivolumab plus chemotherapy followed by resection for superior sulcus tumour with high PD-L1 expression: A case report.
- Author
-
Nakaya T, Hirai Y, Akamatsu H, Kojima F, Iguchi H, Fusamoto A, Yata Y, Nagai T, Kitahara D, Takakura T, Nishimura Y, and Yamamoto N
- Abstract
The standard treatment for resectable non-small cell lung cancer (NSCLC) located in the superior sulcus is neoadjuvant chemoradiotherapy followed by highly invasive resection. Based on the results of the CheckMate 816 trial, which showed a marked improvement in the efficacy of neoadjuvant chemo-immunotherapy, we report a case of minimally invasive resection after neoadjuvant nivolumab plus chemotherapy for superior sulcus NSCLC, resulting in a pathologic complete response. The patient was a 76-year-old man with a 65-mm right superior sulcus tumour diagnosed as squamous cell carcinoma with 95% PD-L1. After two courses of neoadjuvant nivolumab plus chemotherapy, the tumour was completely resected through an 11-cm right lateral thoracotomy with second rib resection and first rib preservation. No residual tumour cells were observed in the specimen, and the patient had a pathologic complete response. This report represents a new treatment option for superior sulcus tumours., Competing Interests: Hiroaki Akamatsu, Honoraria; Amgen Inc, AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol‐Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Nippon Kayaku. Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Pfizer Inc, Takeda Pharmaceutical Co. Ltd. and Taiho Pharmaceutical Co. Ltd. Advisory role; Amgen Inc, and Janssen Pharmaceutical K.K., Sandoz. Research funding; Amgen Inc, Chugai Pharmaceutical Co. Ltd. and MSD K.K.. Nobuyuki Yamamoto, Honoraria; AbbVie Inc., Accuray Japan K.K., Amgen K.K., AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Guardant Health Japan Corp., Janssen Pharmaceutical K.K., Merck Biopharma Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., MSD K.K., Kyorin Pharmaceutical Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Pfizer Inc, Takeda Pharmaceutical Co. Ltd. and Taiho Pharmaceutical Co. Ltd., Terumo Corp., Tsumura & Co.. Advisory role; Amgen K.K., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd. Research funding; AbbVie Inc., Amgen K.K., Asahi Kasei Corporation, AstraZeneca K.K., A2 Healthcare Corporation, Boehringer Ingelheim Japan Inc., Bristol‐Myers Squibb K.K., Chugai Pharmaceutical Co. Ltd., EPS Holdings, Inc., IQVIA Services Japan K.K., Janssen Pharmaceutical K.K., Mebix, Inc., MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd.. Data safety Monitoring Board: AstraZeneca K.K. All other authors declare no conflict of interest., (© 2024 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.)
- Published
- 2024
- Full Text
- View/download PDF
9. Involvement of Cannabinoid Receptors and Adenosine A2B Receptor in Enhanced Migration of Lung Cancer A549 Cells Induced by γ-Ray Irradiation.
- Author
-
Oyama M, Sakamoto M, Kitabatake K, Shiina K, Kitahara D, Onozawa S, Nishino K, Sudo Y, and Tsukimoto M
- Subjects
- Humans, A549 Cells, Actins, Receptor, Adenosine A2B, Receptors, Cannabinoid, Cannabinoids pharmacology, Cannabinoids metabolism, Lung Neoplasms radiotherapy
- Abstract
Residual cancer cells after radiation therapy may acquire malignant phenotypes such as enhanced motility and migration ability, and therefore it is important to identify targets for preventing radiation-induced malignancy in order to increase the effectiveness of radiotherapy. G-Protein-coupled receptors (GPCRs) such as adenosine A2B receptor and cannabinoid receptors (CB1, CB2, and GPR55) may be involved, as they are known to have roles in proliferation, invasion, migration and tumor growth. In this study, we investigated the involvement of A2B and cannabinoid receptors in γ-radiation-induced enhancement of cell migration and actin remodeling, as well as the involvement of cannabinoid receptors in cell migration enhancement via activation of A2B receptor in human lung cancer A549 cells. Antagonists or knockdown of A2B, CB1, CB2, or GPR55 receptor suppressed γ-radiation-induced cell migration and actin remodeling. Furthermore, BAY60-6583 (an A2B receptor-specific agonist) enhanced cell migration and actin remodeling in A549 cells, and this enhancement was suppressed by antagonists or knockdown of CB2 or GPR55, though not CB1 receptor. Our results indicate that A2B receptors and cannabinoid CB1, CB2, and GPR55 receptors all contribute to γ-radiation-induced acquisition of malignant phenotypes, and in particular that interactions of A2B receptor and cannabinoid CB2 and GPR55 receptors play a role in promoting cell migration and actin remodeling. A2B receptor-cannabinoid receptor pathways may be promising targets for blocking the appearance of malignant phenotypes during radiotherapy of lung cancer.
- Published
- 2024
- Full Text
- View/download PDF
10. Mixed neuroendocrine-non-neuroendocrine neoplasm of the ampulla of Vater: a case report.
- Author
-
Date K, Tatsuguchi T, Shimokawa Y, Niina Y, Kitahara D, Kuga H, Tamiya S, Nishihara K, and Nakano T
- Abstract
Background: Mixed neuroendocrine-non-neuroendocrine neoplasms of the ampulla of Vater are rare and heterogenous, making it difficult to achieve a definitive preoperative diagnosis. Herein, we describe a patient in whom a provisional diagnosis of mixed neuroendocrine-non-neuroendocrine neoplasm of the ampulla of Vater was made preoperatively., Case Presentation: Computed tomography revealed an enhancing periampullary tumor in a 69-year-old man with obstructive jaundice. Subsequent duodenoscopy revealed an ulcerated lesion in the swollen ampulla of Vater, from which six biopsies were collected. Pathological examination revealed adenocarcinoma in five of them. The remaining one was a neuroendocrine neoplasm according to immunohistochemical analysis. With a provisional diagnosis of mixed neuroendocrine-non-neuroendocrine neoplasm of the ampulla of Vater, the patient underwent subtotal stomach-preserving pancreaticoduodenectomy with modified Child's reconstruction and was discharged without complications. Pathological examination revealed both adenocarcinoma and neuroendocrine carcinomas, each accounting for ≥ 30% of the tumor, resulting in a definitive diagnosis of mixed neuroendocrine-non-neuroendocrine neoplasm of the ampulla of Vater. Lymph node metastases with neuroendocrine components were also observed. Adjuvant chemotherapy was not administered because of the patient's renal dysfunction. Liver and lymph node metastases were detected 2 months after surgery, the neuroendocrine component being considered responsible for that relapse. The patient underwent platinum-based chemotherapy at 50% dosage, which initially resulted in significant tumor shrinkage; however, he died 6 months after surgery., Conclusions: While these tumors' heterogeneity make definitive preoperative diagnosis of mixed neuroendocrine-non-neuroendocrine neoplasm of the ampulla of Vater difficult, the possibility of this disease can be considered by careful examination. Further study is needed to establish the optimal diagnostic criteria and treatment strategy., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
11. Ligamentum Flavum Hematoma Accompanied by Intraspinal and Extraspinal Hematomas: A Case Report.
- Author
-
Sugita T, Tomari S, Kitahara D, Ito Y, and Kato G
- Abstract
Studies on ligamentum flavum hematoma (LFH) have been gradually increasing; however, no study has reported an LFH spreading to the intraspinal and extraspinal spaces. The purpose of this report is to discuss this rare condition and report that extraspinal hematoma can be formed by LFH. The authors present the case of a 78-year-old man presented with right L5 radiculopathy caused by a space-occupying lesion with intraspinal and extraspinal expansions at the L4-L5 vertebral levels demonstrated on MRI. We tentatively diagnosed these lesions as intraspinal and extraspinal hematomas originating from the ligamentum flavum based on the chronological changes seen on MRI and computed tomography-based needle biopsy. After the extirpation of these lesions, the symptoms were relieved. Three months later, the patient could walk without a cane. From the intraoperative findings and pathological examination, we concluded that the extraspinal hematoma in paravertebral muscle was caused by an LFH of unknown etiology. This case report describes the difficulty in diagnosing LFH accompanied by an extraspinal hematoma with wide-spreading expansion and highlights the usefulness of repetitive MRI over time in capturing chronological changes of the hematoma. As far as we know, this is the first study on an LFH accompanied by an extraspinal hematoma in the multifidus., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2023, Sugita et al.)
- Published
- 2023
- Full Text
- View/download PDF
12. Histological background of dedifferentiated solitary fibrous tumour.
- Author
-
Yamada Y, Kohashi K, Kinoshita I, Yamamoto H, Iwasaki T, Yoshimoto M, Ishihara S, Toda Y, Ito Y, Kuma Y, Yamada-Nozaki Y, Koga Y, Hashisako M, Kiyozawa D, Kitahara D, Narutomi F, Kuboyama Y, Nakamura T, Inoue T, Mukai M, Honda Y, Toyokawa G, Tsuchihashi K, Fushimi F, Taguchi K, Nishiyama K, Tamiya S, Oshiro Y, Furue M, Nakashima Y, Suzuki S, Iwaki T, and Oda Y
- Subjects
- Antigens, CD34 metabolism, Biomarkers, Tumor analysis, Cyclin-Dependent Kinase Inhibitor p16 metabolism, Humans, Retinoblastoma Protein metabolism, Tumor Suppressor Protein p53 metabolism, Solitary Fibrous Tumors genetics, Solitary Fibrous Tumors pathology
- Abstract
Aims: Dedifferentiation is a histological phenomenon characterised by abrupt transition of histology to a sarcomatous component with high-grade malignant potential in solitary fibrous tumour (SFT). The authors histologically reviewed SFT cases to reveal the histological background of dedifferentiated SFTs., Methods: Clinicopathological and histopathological findings of 145 SFT cases were reviewed. Immunohistochemical staining and genetic analysis were also performed., Results: The non-dedifferentiated components showed a cellular component in 45 of 145 (31%), high mitotic rate (≥4/10 high-powered field) in 12 of 145 (8.2%) tumours, necrosis in 7 of 145 (4.8%) tumours, multinodular growth pattern in 39 of 132 (29.5%) available tumours and intratumoural fibrous septa in 37 of 131 (28.2%). Immunohistochemically, the non-dedifferentiated components were positive for CD34 in 128 of 141 (90.7%), bcl-2 in 101 of 133 (75.9%), nuclear pattern of β-catenin in 64 of 127 (50.3%) and p16 in 22 of 140 (15.7%). Loss of Rb protein expression was detected in 17 of 110 (15.4%) cases. Statistically, cellular component, multinodular structure, p16 overexpression and Rb protein loss were significantly associated with dedifferentiation. Moreover, cellular component and multinodular structure were significantly associated with p16 overexpression and Rb protein loss. All the non-deddifferentiated components showed wild type of p53 expression. The dedifferentiated components of all 10 dedifferentiated tumours presented positivity for p16 in 9 of 10 (90%) and mutational type of p53 in 5 of 10 (50%). Loss of Rb protein expression was detected in 6 of 10 (60%)., Conclusions: The authors propose that cellular or multinodular transformation may be associated with dedifferentiation. They also suggest that cellular and multinodular transformation may be associated with p16 overexpression and Rb downregulation., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
13. Three cases of synovial sarcoma of gastric wall: A case report and review of the literature.
- Author
-
Kuboyama Y, Yamada Y, Kohashi K, Toda Y, Kawakami K, Kitahara D, Nishiyama K, Hiraki Y, Oya M, and Oda Y
- Subjects
- Biomarkers, Tumor analysis, Humans, Male, SMARCB1 Protein genetics, Sarcoma, Synovial diagnosis, Sarcoma, Synovial pathology, Soft Tissue Neoplasms diagnosis, Soft Tissue Neoplasms pathology, Stomach Neoplasms diagnosis, Young Adult, Oncogene Proteins, Fusion genetics, Sarcoma, Synovial genetics, Soft Tissue Neoplasms genetics, Stomach Neoplasms genetics
- Abstract
Synovial sarcoma (SS) is a malignant soft tissue neoplasm that occurs in various parts of the human body, but most commonly affects the extremities. Its diagnosis of synovial sarcoma often requires adjunctive techniques such as immunohistochemical staining and molecular studies, especially for synovial sarcoma at unusual locations. SS at a gastrointestinal location is exceedingly rare. We report here three cases of primary gastric synovial sarcoma. Malignant gastric mesenchymal tumor has many differential diagnoses other than synovial sarcoma, such as gastrointestinal stromal tumor (GIST), leiomyosarcoma, schwannoma, malignant peripheral nerve sheath tumor (MPNST) and so on. In our three cases, using reverse transcription polymerase chain reaction (RT-PCR) and direct sequencing, we detected an SS18-SSX1 fusion gene, which is specific to synovial sarcoma. In addition, we found the reduced expression of SMARCB1/INI1 in the tumor cells in two of the three cases. Through histopathological, immunohistochemical, and molecular analyses, we confirmed the diagnosis of primary gastric synovial sarcoma., (Copyright © 2021 Elsevier GmbH. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
14. Lethal multiple colon necrosis and perforation due to fulminant amoebic colitis: a surgical case report and literature review.
- Author
-
Tomino T, Ninomiya M, Minagawa R, Matono R, Yumi Oshiro, Kitahara D, Izumi T, Taniguchi D, Hirose K, Kajiwara Y, Minami K, and Nishizaki T
- Abstract
Background: Amoebiasis caused by the protozoan species Entamoeba histolytica rarely develops into fulminant amoebic colitis (FAC), but when it does, it shows an aggressive clinical course including colonic perforation, necrotizing colitis, and high mortality. Surgical treatment for FAC patients should be carried out urgently. However, even after surgery, the mortality rate can be 40-50%. Although FAC is one of the most unfavorable surgical diseases with a poor prognosis, there are a few reports on the perioperative diagnosis and management of FAC based on autopsy findings. We herein report the surgical case of a 64-year-old man who developed multiple colon necrosis and perforation due to FAC. A detailed autopsy revealed FAC as the cause of death. Additionally, we reviewed the existing literature on FAC patients who underwent surgery and followed their perioperative diagnosis and management., Case Presentation: A 64-year-old man presented with anorexia, diarrhea, and altered consciousness on arrival to our hospital. Computed tomography revealed a large mass in the upper right lobe of his lung, and the patient was admitted for close investigation. Bloody diarrhea, lower abdominal pain, and hypotension were observed soon after admission. Urgent abdominal contrast-enhanced computed tomography scan revealed extensive intestinal ischemia, intestinal pneumatosis, and free intra-abdominal gas. The preoperative diagnosis was bowel necrosis and perforation with intussusception of the small intestinal tumor. Emergency subtotal colectomy and enterectomy were performed soon after the contrast-enhanced computed tomography. He was taken to an intensive care unit after surgery. However, he could not recover from sepsis and died with disseminated intravascular coagulation and multiple organ failure on the 10th-day post-surgery. A histopathological examination of the resected colon showed transmural necrosis and massive amoebae invasion. He was diagnosed with FAC. An autopsy revealed that he had developed pulmonary large cell carcinoma with small intestinal metastasis. The death was caused by intestinal ischemia, necrosis and the perforation of the residual bowel caused by amoebae invasion., Conclusions: Since FAC is a lethal disease with a high mortality rate and antibiotic therapies except metronidazole are ineffective, preoperative serological testing and perioperative metronidazole therapy in FAC patients can dramatically improve their survival rates.
- Published
- 2021
- Full Text
- View/download PDF
15. Clinicopathological review of solitary fibrous tumors: dedifferentiation is a major cause of patient death.
- Author
-
Yamada Y, Kohashi K, Kinoshita I, Yamamoto H, Iwasaki T, Yoshimoto M, Ishihara S, Toda Y, Itou Y, Koga Y, Hashisako M, Nozaki Y, Kiyozawa D, Kitahara D, Inoue T, Mukai M, Honda Y, Toyokawa G, Tsuchihashi K, Matsushita Y, Fushimi F, Taguchi K, Tamiya S, Oshiro Y, Furue M, Nakashima Y, Suzuki S, Iwaki T, and Oda Y
- Subjects
- Adolescent, Adult, Aged, Cell Dedifferentiation, Child, Child, Preschool, Female, Humans, Male, Middle Aged, Young Adult, Solitary Fibrous Tumors mortality, Solitary Fibrous Tumors pathology
- Abstract
Solitary fibrous tumor (SFT) is a soft-tissue neoplasm of intermediate malignant potential, presenting a wide histopathological spectrum. Poorer prognosis of hemangiopericytoma of the central nervous system (CNS), hypoglycemic SFT, and dedifferentiation are well-known characters of SFT, but their clinical significance were not demonstrated enough by large-sized study. Here, the clinicopathological features of SFTs are reviewed and the relationship between genetics and clinicopathological features is examined using 145 SFT cases. All cases were STAT6 IHC-positive and/or NAB2-STAT6 fusion gene-positive. Tumor location was classified into three categories: 30 pleuropulmonary, 96 non-pleuropulmonary/non-central nervous system (CNS), and 18 CNS tumors. The tumor developed recurrence in 21 of 93 available cases (22.5%), metastasis in 11 of 93 (11.8%), and tumor death in 9 of 93 (9.6%). Hypoglycemia occurred in 2 primary tumors and 1 metastatic tumor among 63 reviewable cases, and dedifferentiation occurred in 10 cases (6.8%) including 6 primary tumors, 2 recurrent tumors, and 2 metastatic tumors. Recurrence was positively associated with CNS location (p = 0.0109) and hypoglycemia (p = 0.001); metastasis was positively associated with CNS location (p = 0.0231), hypoglycemia (p < 0.0001), and dedifferentiation (p < 0.0001), while metastasis was negatively correlated with pleural location (p = 0.0471). Tumor death was positively associated with male sex (p = 0.0154), larger size (p = 0.0455), hypoglycemia (p < 0.0001), and dedifferentiation (p < 0.0001). Multivariate analysis revealed independent statistical significance of dedifferentiation for overall survival (p = 0.0467). Exon variant of the fusion gene had no statistical correlation with clinical outcome. In conclusion, dedifferentiation is a major prognostic factor of SFT, and specific location such as cerebromeningeal and intra-abdominal site and hypoglycemia also had a high risk for unfavorable prognosis.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.